ストックスクリーナーアプリを入手
10.01
1.01%
0.10
アフターアワーズ：
10.07
0.06
+0.60%
Capricor Therapeutics Inc (CAPR) 最新ニュース
CAPR Stock Sinks As Investors Brace For Imminent FDA Call On Deramiocel - Stocktwits
Capricor Therapeutics (NASDAQ:CAPR) Healthcare Strategy Focus - Kalkine Media
Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Morningstar
CAPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Activist Investor Sounds Alarm on Capricor’s Cash Burn - TradingView
/C O R R E C T I O N — Kessler Topaz Meltzer & Check, LLP/ - Morningstar
Activist Investor Kaos Capital Demands Board Overhaul at Capricor Ahead of FDA Decision on DMD Therapy - finance.biggo.com
INVESTOR DEADLINE: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors with Substantial Losses Have Opportunity to Lead Capricor Class Action Lawsuit Before September 28, 2026 Deadline - PR Newswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - lincolnjournal.com
Capricor Stock Faces Securities-Fraud Case as FDA Review Stays Open - TechStock²
Kaos Capital Pushes for Strategic Board Meeting at Capricor Ther - GuruFocus
Kaos Capital pushes for board changes at Capricor Therapeutics - Investing.com
Kaos Capital pushes for board changes at Capricor Therapeutics By Investing.com - Investing.com Canada
Capricor shareholder cites ~$80.2M cash drop and seeks spending cuts - Stock Titan
Kaos Capital Calls on Capricor (NASDAQ: CAPR) Shareholders - Yahoo Finance
Duchenne Cell Therapy Shifts Its Target from the Heart to Arm Function as Decision Date Slips - Medical Daily
Shareholder pressures Capricor; Lilly dives deeper into vaccines - Yahoo Finance
Capricor (CAPR) Q2 2026 Earnings Call Transcript - AOL.com
Capricor Draws Investor Attention As Shareholder Kaos Capital Pushes For Board Shakeup Ahead Of Key FDA Decision On DMD Therapy - Stocktwits
Capricor (CAPR) Q2 2026 Earnings Call Transcript - The Motley Fool
Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to Contact the Firm to Learn About Their Legal Rights - The Globe and Mail
Deadline Alert: Capricor Therapeutics, Inc. (CAPR) - GlobeNewswire
Capricor Therapeutics (CAPR) Faces Valuation Challenges Ahead of FDA Decision - GuruFocus
Capricor Therapeutics, Inc. Investors Have Opportunity to - GlobeNewswire
CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics Securities LawsuitContact SueWallSt - Morningstar
Capricor Therapeutics (CAPR) Faces Market Pressure Amid FDA Conc - GuruFocus
Capricor Therapeutics Shareholder Alert: ClaimsFiler - GlobeNewswire
Capricor slips on potential Deramiocel rejection (CAPR:NASDAQ) - Seeking Alpha
CAPR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesCAPR - PR Newswire
Piper Sandler Downgrades Capricor Therapeutics, Cuts Target to $2 - scanx.trade
CAPRICOR THERAPEUTICS, INC. (CAPR) SHAREHOLDER ALERT - GlobeNewswire
$Capricor Therapeutics (CAPR.US)$ FDA APPROVAL 2026-08-22 in two days get ready!!! - Moomoo
CAPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Capricor Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Kaplan Fox & Kilsheimer LLP Alerts Capricor Therapeutics, Inc. (N - The National Law Review
Capricor (CAPR) Closed 58% Higher on an FDA Lifeline. Is Approval Really Back on Track? - Yahoo Finance
Kaplan Fox & Kilsheimer LLP Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to the Lead Plaintiff Deadline on September 28, 2026 - Barchart.com
Capricor Therapeutics (CAPR): Millennium stake slips under 5% - Stock Titan
ROSEN, A LEADING NATIONAL FIRM, Encourages Capricor - GlobeNewswire
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - TMX Newsfile
CAPR EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 29, 2026 - TMX Newsfile
Bronstein, Gewirtz & Grossman LLC Urges Capricor - GlobeNewswire
INVESTOR ALERT: Capricor Therapeutics, Inc. (CAPR) Class Action Lawsuit: Investors Face September 28, 2026, Deadline - NewMediaWire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - Morningstar
CAPR Investor Reminder: Capricor Therapeutics Securities - GlobeNewswire
Capricor Therapeutics, Inc. Notice of September 28, 2026 - GlobeNewswire
INVESTOR ALERT: Capricor Therapeutics, Inc. (CAPR) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NewMediaWire
Robbins LLP Urges CAPR Stockholders to Contact the Firm for Information About the Class Action Against Capricor Therapeutics, Inc. - WBOC TV
CAPR INVESTOR REMINDER: Capricor Therapeutics, Inc. Investors Have Until September 28, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role - lincolnjournal.com
Kaplan Fox & Kilsheimer LLP Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before September 28, 2026 - Barchart.com
All Eyes On Capricor Therapeutics Ahead Of Crucial Hearing On DMD Therapy Agreement – CAPR Stock Jumps 6% - Stocktwits
Lost Money on Capricor Therapeutics, Inc. (CAPR)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - Morningstar
CAPR Stock Sinks After-Hours: Capricor Launches Legal Fight Over DMD Therapy Rollout Ahead Of FDA Review - Stocktwits
Kaplan Fox Class Action Reminder: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Lead Plaintiff Deadline is September 28, 2026 - The Globe and Mail
CAPR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 29, 2026 - TMX Newsfile
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (CAPR) - TMX Newsfile
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces - GlobeNewswire
Q3 EPS Estimate for Capricor Therapeutics Cut by Analyst - MarketBeat
Capricor Therapeutics (CAPR) Could Be 89% Undervalued Following Deramiocel And Loss Concerns - Sahm
CAPR Stock News: Capricor Therapeutics Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 64% Stock Drop - PR Newswire
CAPR Stock Alert: Capricor Therapeutics, Inc. (CAPR) Reports Q2 Earnings Amid Ongoing Securities Class Action LawsuitHagens Berman - PR Newswire
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Rating of "Hold" from Brokerages - MarketBeat
CAPR Stock Alert: Capricor Therapeutics, Inc. (CAPR) Reports Q2 E - The National Law Review
CAPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Capricor Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
CAPR Stock Alert: Capricor Therapeutics, Inc. (CAPR) - GlobeNewswire
Kaplan Fox Shareholder Alert: Deadline to Lead in the Securities Fraud Lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) is September 28, 2026 - The Globe and Mail
0.33%
0.25%
大文字化:
|
ボリューム (24 時間):